Grants for Nonprofits - Health

This funding opportunity supports new entrepreneurs in small businesses by providing resources for their career development and research efforts, helping them grow their skills in technology and healthcare innovation.

This grant provides funding to organizations that support children and young people by addressing their basic needs, promoting health care access, and fostering community support, with a focus on prevention and early intervention.

This grant provides funding to nonprofit organizations and government entities for youth summer programs that promote education and social interaction, or for senior citizen programs that encourage entertainment and cognitive engagement in the Lockwood area.

The Ramsey County Trusted Messenger Initiative Grants aim to foster and develop innovative approaches for delivering public health services, resources, and information. The overarching mission alignment for this initiative is to address health inequalities, language barriers, and isolation from county services, particularly for racially and ethnically diverse communities, immigrant families, and new Minnesotans. By empowering trusted messengers, the program seeks to ensure equitable access to crucial public health support and information, aligning with a strategic goal of community well-being and health equity. The program targets specific beneficiaries across several priority areas. For "Healthy Communities," the focus is on racially and ethnically diverse communities, immigrant families, and new Minnesotans, with an impact goal of increasing awareness and access to culturally informed public health information in areas like healthy aging, Hmong health, sexual violence, adolescent health, and child/teen checkups. The "Women, Infants, and Children (WIC)" priority specifically targets pregnant and postpartum women and their children, especially early in pregnancy and multigenerational African American populations, with the goal of increasing WIC program awareness and referrals for healthy food, nutrition education, and lactation support. The "Family Health and Home Visiting" area is dedicated to promoting equity in birth outcomes for diverse communities, including African American, Native American, Latino/x, and immigrant populations, aiming to support families, fathers, and other caregivers in navigating pre- and post-birth care with a holistic approach. Key priorities also include "Clinical Services," which seeks to increase awareness and access to vaccines, immunizations, tuberculosis care, sexual and reproductive health services (HIV/STD testing, syringe services), wound care, and naloxone training for people using drugs. "Environmental Health" prioritizes finding creative ways to boost participation in food scraps pick-up, hazardous waste drop-off, and electronics recycling programs, especially within racially and ethnically diverse communities, while also raising awareness of the Environmental Service Center. Finally, "Climate Action" aims to increase awareness of climate change's health impacts and county resources to mitigate them. The expected outcomes and measurable results revolve around enhanced public health service delivery and increased community engagement. The initiative anticipates awarding approximately 10 grants, each up to $36,000, with an emphasis on reaching underserved populations. Success will be measured by improved access to health information, increased participation in public health programs, and a reduction in health disparities among the targeted communities. The foundation's strategic priorities are evident in its encouragement of applications from organizations that have not previously contracted with Ramsey County, ethnically and culturally diverse, women-owned, or veteran-owned organizations, and those with fewer than 50 employees, indicating a theory of change that values community-led, grassroots efforts and seeks to broaden the network of trusted service providers. Organizations serving adjacent counties like Dakota County are also encouraged, signaling a broader regional impact goal.

This grant provides funding for collaborative research resources and services to support multiple independent vision researchers, enhancing their ability to conduct high-quality studies on the visual system and its disorders.

The New York State Department of Health, Office of Primary Care and Health Systems Management, Bureau of Emergency Medical Services and Trauma Systems is issuing the County Emergency Medical Services Support Grant. This grant aims to support county-level EMS systems in New York State. Eligible applicants are counties within New York State. Applications must be submitted online via the Statewide Financial System by June 26, 2024.

The Elmina B. Sewall Foundation's 2024 Legacy Grant program is designed to honor Mrs. Sewall's enduring interests and philanthropic legacy. The foundation's mission alignment is rooted in supporting a select group of organizations with whom Mrs. Sewall had personal relationships and affinity, and who continue to advance the work she funded during her lifetime. This reflects a strategic priority to sustain and perpetuate the impact of her personal philanthropy, acting as a direct extension of her lifelong commitment. The primary target beneficiaries for this grant are organizations that align with Mrs. Sewall's historical funding priorities. These include 501(c)(3) federal tax-exempt organizations, public schools, public agencies working for the State of Maine, and Indian tribal governments (and their political subdivisions) recognized by the Department of the Interior. The impact goal is to ensure the continued vitality and effectiveness of these established partnerships, allowing them to further their work in areas important to Mrs. Sewall. The program's priorities and focuses are centered on maintaining the integrity of Mrs. Sewall's philanthropic vision. The grant specifically seeks to support organizations that demonstrate a continued commitment to the types of initiatives she championed. While specific measurable results are not explicitly detailed beyond the continuation of existing work, the expected outcomes revolve around sustaining the impact of these organizations over the grant duration, which can be 12, 24, or 36 months. The theory of change implicit in this program is that by providing consistent, multi-year funding to trusted partners, the foundation can ensure the long-term success and stability of programs that align with its founder's values. The foundation's strategic priorities are to honor its founder's legacy by supporting organizations that were meaningful to her, ensuring that her lifetime of philanthropy continues to resonate within the community. The Legacy Grant embodies this by providing stable support, allowing these organizations to focus on their core missions. This approach emphasizes continuity and relationship-building as key drivers for achieving sustained impact and honoring the philanthropic vision of Elmina B. Sewall.

NIEHS invites applications for cooperative agreements to support the development of model programs for the training and education of workers engaged in activities related to hazardous materials and waste generation, removal, containment, transportation and emergency response. This funding opportunity announcement aims to prevent work-related harm through safety and health training. The training programs will transmit skills and knowledge to workers in how best to protect themselves and their communities from exposure to hazardous materials encountered during hazardous waste operations, hazardous materials transportation, environmental restoration of contaminated facilities or chemical emergency response. A variety of sites, such as those involved with chemical waste cleanup and remedial action and transportation-related chemical emergency response, may pose severe health and safety concerns to workers and the surrounding communities. These sites contain many hazardous substances, sometimes unknown, and often a site is uncontrolled. A major goal of the Worker Training Program (WTP) is to support institutional competency-building for the development and delivery of model training and education programs.

This funding opportunity is designed to create a standardized training program for coroners, medical examiners, and death investigators in New York State to improve their skills and knowledge in line with national standards.

This funding opportunity provides financial support to academic and research institutions for establishing interdisciplinary centers that advance research on the impact of environmental factors on human health and promote community engagement in public health initiatives.

The purpose of this notice of funding opportunity (NOFO) is to solicit applications to participate in the Immunobiology of Xenotransplantation Cooperative Research Program (IXCRP), a multi-center program dedicated to resolving immunologic and physiologic barriers to safe and efficacious xenotransplantation using preclinical pig to nonhuman primate (NHP) or human decedent models of pancreatic islet, kidney, heart, lung, or liver xenotransplantation. Transplantation is often the preferred or only therapy for end-stage organ disease. In 2023, 46,630 organ transplants were performed in the United States. In addition, transplantation of pancreatic islets offers a potential therapy for individuals with type 1 diabetes whose disease is not effectively managed with exogenous insulin. Unfortunately, with over 103,500 adults and children on the United Network for Organ Sharing (UNOS) waiting list, those in need of a transplant greatly exceed the number of available organs. It is estimated that 20 people on average die each day waiting for a transplant. Xenotransplantation offers a potential interim or definitive solution to the severe shortage of human organs and pancreatic islets. Pigs are the primary species of interest as xenograft donors due to their favorable reproductive capacity, and anatomical and physiological similarities to humans. However, there are multiple barriers to successful clinical xenotransplantation, including immunologic rejection of non-human organs and tissues by the human immune system, physiological differences between non-human and human molecules that prevent proper functioning of various biochemical pathways, and potential transmission of zoonoses. To address these challenges, the IXCRP was established by the National Institute of Allergy and Infectious Diseases (NIAID) in 2005 with a co-fund for type 1 diabetes from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (RFA-AI-04-042). Subsequently, in 2010, the program was renewed solely by NIAID (RFA-AI-09-035), in 2015 (RFA-AI-14-047 and RFA-AI-14-048), and in 2020 (RFA-AI-19-042 and RFA-AI-19-043). IXCRP investigators and other researchers in the field have made significant advances over the past two decades, and NIAID is committed to support this challenging area of research. Historically, the most significant hurdle to successful xenotransplantation was hyperacute rejection caused by preformed, xenoreactive naturally-occurring antibodies (XNA) that destroy the xenograft within hours post-transplant. The primary target of XNA is a carbohydrate epitope, galactose-alpha-(1,3)-galactose (Gal), which is not present in humans and Old World NHPs. To overcome this hurdle, two decades ago, the enzyme responsible for terminally linking Gal onto oligosaccharide chains, alpha-1,3 glycosyltransferase (GT), was knocked out in genetically modified pigs. Xenografts from GT knockout (GTKO) pigs elicit substantially less severe hyperacute rejection in NHPs. Cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) gene knockouts and mutations to beta-1,4-N-acetyl-galactosaminyltransferase 2 (B4GALNT2) were similarly engineered to reduce reactivity to other notable XNA to pig carbohydrate antigens, namely N-glycolylneuraminic acid-modified glycans and SDa swine blood group antigen, respectively. Over the last decade, application of CRISPR-Cas 9 technology combined with somatic cell nuclear transfer cloning has significantly accelerated the pace of multi-gene modification and donor pig production. Additional genetic modifications, most on the GTKO background, were developed to address key species-to-species incompatibilities and create more human-like organs. These include the insertion of human complement regulatory proteins to minimize the deleterious effects of the complement cascade in antibody-mediated rejection, human thrombomodulin and/or tissue factor pathway inhibitor to overcome coagulation pathway dysfunction, and human anti-inflammatory and/or immune suppressive genes to reduce immune activation contributing to graft rejection. These strategies have dramatically reduced the frequency and severity of hyperacute rejection and have prolonged survival in pig-to-NHP xenotransplantation models for up to 4 years. Success in prolonging xenograft survival in the pig-to-NHP model allows more in-depth investigation of the remaining immunologic and physiologic issues that must be addressed in order to achieve safe and efficacious clinical xenotransplantation. These include physiologic differences that influence xenograft function and long-term survival, and risks associated with zoonoses. Transmission of pathogenic zoonoses to a human recipient and, potentially, the general population is a concern. To reduce this risk, animals used for xenotransplantation are bred in specific-pathogen-free conditions, weaned early or caesarian-derived, and routinely screened to eliminate most, if not all, known zoonotic agents. Porcine Cytomegalovirus (PCMV) is a swine pathogen known to have deleterious effects on xenograft survival. In the first human patient to receive a cardiac xenotransplant, conventional testing failed to detect latent PCMV in the donor pig and the virus reactivated post-transplant. The extent to which PCMV reactivation contributed to the patient’s death is unknown; however, this event underscores the need for sensitive and reliable assays to detect both latent and active infection with PCMV. Porcine endogenous retroviruses (PERV), another potential zoonotic threat, were successfully inactivated in a line of pigs through a combination of CRISPR-Cas9 gene-editing and somatic cell nuclear transfer, further highlighting the potential of these technologies to both protect against immunologic attack and reduce the risk of zoonoses. The field of xenotransplantation has recently witnessed an expansion in research models beyond NHP recipients to include an evaluation of safety, feasibility, and short-term outcomes (2 – 60 days) in humans declared to have irreversible loss of brain function (individuals with brain death, also referred to as human decedents) maintained on cardiopulmonary support. These experiments, using varying genetically modified pig hearts and kidneys transplanted into human decedents whose organs were declined for allotransplantation based on organ quality, have demonstrated early hemodynamic stability, an absence of hyperacute rejection, and basic organ functionality under immunosuppression. No chimerism or transmission of porcine retroviruses were detected; however, many of these experiments have demonstrated thrombotic microangiopathy and/or antibody-mediated injury. As of the time of this writing, medical teams that include IXCRP-funded investigators have performed two pig-to-human orthotopic heart transplants under expanded access (compassionate use) authorization from the FDA. The two xenograft recipients expired at 8 and 6 weeks, respectively. These initial clinical xenotransplants demonstrated good early xenograft function but also highlighted fundamental gaps in our knowledge of 1) critical pathways leading to inflammation and graft failure, 2) best practices for zoonotic viral surveillance and treatment, 3) optimal design of the donor pig, and 4) postoperative immunosuppression regimen. These knowledge gaps must be addressed prior to broader clinical translation. Scope and Research Objectives The re-issue of the IXCRP will support research projects centered around preclinical NHP and/or human decedent models of porcine pancreatic islet, kidney, heart, lung, or liver xenotransplantation. The research objectives must address one or more of the remaining key immunologic and physiologic barriers to achieving safe and efficacious xenotransplantation, including issues affecting engraftment, survival, and function of xenografts. Research foci may include 1) development or optimization of the models themselves, including genetic modifications of the pig-donor to address FDA concerns, as well as refinement of surgical xenotransplantation techniques, 2) development or optimization of the immunosuppression (IS) regimen to prevent rejection and minimize toxicity, 3) characterization and resolution of physiological and immunological barriers to long-term xenograft survival, and 4) development or optimization of strategies to screen for and prevent pathogen transmission to recipients. Examples of research topics may include, but are not limited to the following: Elucidation of the cellular and molecular mechanisms of and development of strategies to prevent hyperacute, acute, and chronic xenograft rejection; Characterization of the recipient’s innate and adaptive immune responses to the xenograft; Evaluation of regimens to induce and maintain immune tolerance to xenografts and/or delineation of cellular and molecular mechanisms promoting xenograft tolerance; Development and characterization of strategies to prolong xenograft survival in life-supporting xenotransplantation models; Development of approaches to eliminate or minimize the use of immunosuppressive drugs through genetic modifications of donor organs/tissues/cells, utilization of encapsulation techniques, or other tolerogenic approaches; Characterization of and application of approaches to address differences in the anatomical, physiological, and/or endocrinological features of donor pig organs, tissues, or cells that limit a xenograft’s survival and function in NHP or human decedent recipients; Delineation and study of cross-match differences between pigs and NHPs or humans; Development and testing of tools/approaches to diagnose, monitor, and treat porcine zoonoses in human decedent models; Development and testing of tools/approaches to diagnose, monitor, and treat xenograft rejection; and Development and testing of tools/approaches to diagnose, monitor, and treat causes of xenograft dysfunction other than immunologic rejection. Applications proposing any of the following will be considered non-responsive and will not be reviewed: Pig-to-NHP xenotransplantation studies of any organs, tissues, or cells other than pancreatic islets, kidney, heart, lung, or liver. Small animal models of xenotransplantation, such as rodent models, unless the model is proposed only as an in vivo bioassay of large animal immune function (e.g., trans in vivo delayed type hypersensitivity assay); Clinical trials or clinical/human studies of xenotransplantation; (only preclinical human decedent model research is allowed). Studies of zoonotic agents or infections, except for those studies designed to prevent transmission of, or improve diagnosis, monitoring, or treatment of zoonotic infections in xenograft recipients. Studies focused on HIV/AIDS-related research. Applications that do not include annual milestones. Applications that propose studies in human decedents but do not include a Human Decedent Research Plan. Milestones The research plan must include explicit, detailed, and quantitative annual milestones. These milestones will be used by NIAID program staff to assess annual progress and support funding decisions. Steering Committee Program Directors/Principal Investigators (PD(s)/PI(s)) of awards funded under this program will form a Steering Committee after award. The Steering Committee will serve as the main governing body of the IXCRP. At annual meetings, the Steering Committee will review progress of xenotransplantation projects, provide guidance and recommendations to investigators regarding study implementation and conduct, identify scientific opportunities, emerging needs, and impediments to success, and encourage collaborations among consortium members. The voting members of the Steering Committee will include the PD/PI (contact PI) from each single project U01 award and the PD/PI (contact PI) plus one project leader from each multi-project U19 award. Additional PDs/PIs, Project Leaders, Core Leaders, and the NIH Project Scientist will serve as non-voting Steering Committee members. All IXCRP investigators will be required to accept and implement common guidelines and procedures approved by the Steering Committee. Applicants are encouraged to consider using the following NIAID-supported programs: The Immunology Database and Analysis Portal (ImmPort) The Immunology Database and Analysis Portal (ImmPort) program will provide support for public sharing of research data and experimental protocols of the IXCRP. ImmPort is a NIAID-funded data sharing platform, which has developed templates for data collection, standardization, and sharing from various NIAID-supported research programs. The IXCRP recipients are encouraged to participate with ImmPort in developing data standards for IXCRP-specific data types, where applicable, and be responsible for collecting and submitting data and documents into ImmPort. The IXCRP Steering Committee will provide information, consistent with the goals of the program and NIH policy, regarding research data and experimental protocol sharing within the IXCRP and with the public. The National Swine Resource and Research Center (NSRRC) The Office of Research Infrastructure Programs within the Division of Program Coordination, Planning, and Strategic Initiatives in the Office of the NIH Director supports the National Swine Resource and Research Center (NSRRC), which is co-sponsored by NIAID and the National Heart, Lung, and Blood Institute (NHLBI). The NSRRC was established in 2003 to develop the infrastructure needed to ensure that biomedical investigators across a variety of disciplines have access to critically needed swine models of human health and disease. The purpose of the NSRRC is to provide the biomedical research community enhanced access to critically needed swine models and to develop genetically modified swine when required for studies involving human health and diseases, including xenotransplantation. NIAID encourages IXCRP-funded investigators to submit relevant cell lines and animal models developed under this NOFO to the NSRRC, when applicable. This U01 NOFO is appropriate for applicants that are proposing a single research project while the companion U19 NOFO (RFA-AI-24-020) should be used for investigators proposing a more complex research program involving 2 or more research projects supported by cores. Applicants are strongly encouraged to discuss the proposed research with NIAID staff listed in the Scientific/Research contact well in advance of the application submission deadline. See Section VIII. Other Information for award authorities and regulations.

This grant provides funding to nonprofit organizations in Burke County, North Carolina, to support programs that improve mental health and well-being for children and families.

This Notice of Funding Opportunity (NOFO) invites applications for sites to participate in the Genomic Medicine eConsult Research Network, hereafter referred to as the eConsult Network. The eConsult Network will consist of 2-3 sites working with NHGRI to conduct research on the impact of and methods for implementing regional clinician-to-clinician genomic medicine eConsult services. Specifically, sites will be funded to research how to best design, develop, and implement regional genomic medicine eConsult services; provide outreach to potential users, including those at underserved settings; and assess the impact on key stakeholders while developing successful implementation strategies and resources that can be broadly shared and adopted.

This grant provides funding to nonprofit organizations in Alaska for projects that strengthen their internal operations and improve their effectiveness through capacity-building initiatives.

This funding opportunity supports innovative research aimed at understanding and addressing mood and psychotic disorders that may arise or worsen during the menopause transition, encouraging collaboration among interdisciplinary researchers.

This funding opportunity provides financial support to academic and nonprofit research institutions for the modernization or construction of shared biomedical research facilities that enhance research capabilities and benefit the broader scientific community.

This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention, treatment or services research for people who use drugs. For the purposes of this FOA, "intervention" may include behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches that prevent the acquisition and transmission of HIV infection, or improve clinical outcomes for persons living with HIV.

This funding opportunity provides financial support to municipalities, non-profits, and community boards in New York State for revitalizing areas impacted by brownfields through planning and environmental assessments.

This funding opportunity supports the development and use of research infrastructure that fosters interdisciplinary collaborations to address complex aging-related scientific questions, particularly benefiting diverse and underserved populations.

This grant provides funding to organizations that aim to improve healthcare delivery and reduce disparities for underserved populations by implementing evidence-based practices and fostering collaboration among healthcare providers, government agencies, and community organizations.